Eva M. Medina-Rodríguez

Dr. Eva M. Medina-Rodríguez


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ABAna Bribián
Ana Bribián
EMEva M. Medina-Rodríguez
Eva M. Medina-Rodríguez
FPFernando Josa Prado
Fernando Josa Prado
IAISABEL GARCIA ALVAREZ
ISABEL GARCIA ALVAREZ
IMIsabel Machín-Díaz
Isabel Machín-Díaz
FCFernando de Castro
Fernando de Castro
Besides giving rise to oligodendrocytes (the only myelin-forming cell in the Central Nervous System (CNS) in physiological conditions), Oligodendrocyte Precursor Cells (OPCs) are responsible for spontaneous remyelination after a demyelinating lesion. They are present along the mouse and human CNS, both during development and in adulthood, yet how OPC physiological behavior is modified throughout life is not fully understood. The activity of adult human OPCs is still particularly unexplored. Significantly, most of the molecules involved in OPC-mediated remyelination are also involved in their development, a phenomenon that may be clinically relevant. In the present article, we have compared the intrinsic properties of OPCs isolated from the cerebral cortex of neonatal, postnatal and adult mice, as well as those recovered from neurosurgical adult human cerebral cortex tissue. By analyzing intact OPCs for the first time with 1H High Resolution Magic Angle Spinning Nuclear Magnetic Resonance (1H HR-MAS NMR) spectroscopy, we show that these cells behave distinctly and that they have different metabolic patterns in function for their stage of maturity. Moreover, their response to Fibroblast Growth Gactor-2 (FGF-2) and anosmin-1 (two molecules that have known effects on OPC biology during development and that are overexpressed in individuals with Multiple Sclerosis (MS)) differs in relation to their developmental stage and in the function of the species. Our data reveal that the behavior of adult human and mouse OPCs differs in a very dynamic way that should be very relevant when testing drugs and for the proper design of effective pharmacological and/or cell therapies for MS.

4 May 2023 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
EMEva M. Medina-Rodríguez
Eva M. Medina-Rodríguez
ACAlyssa A. Cruz
Alyssa A. Cruz
JAJulia Cavati De Abreu
Julia Cavati De Abreu
EBEléonore Beurel
Eléonore Beurel

9 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAna Bribián
Ana Bribián
EMEva M. Medina-Rodríguez
Eva M. Medina-Rodríguez
FPFernando Josa Prado
Fernando Josa Prado
IAISABEL GARCIA ALVAREZ
ISABEL GARCIA ALVAREZ
IMIsabel Machín-Díaz
Isabel Machín-Díaz
FCFernando de Castro
Fernando de Castro
Oligodendrocyte precursor cells (OPCs) are responsible for spontaneous remyelination after a demyelinating lesion. They are present in large parts of the mouse and human central nervous system, both during development and in adulthood, yet how their physiological behaviour is modified throughout life remains largely unknown. Moreover, the activity of adult human OPCs is still not fully understood. Significantly, most of the molecules involved in OPC-mediated remyelination are also involved in their development, a phenomenon that may be clinically relevant. In this article, we have systematically analyzed the intrinsic properties of OPCs isolated from the cerebral cortex of neonatal, postnatal and adult mice, as well as those recovered from neurosurgical adult human cerebral cortex tissue. We also analyze the response of these cells to two molecules that have known effects on OPC biology during development and that are overexpressed in individuals with Multiple Sclerosis (MS): FGF2 and anosmin-1. By analyzing intact OPCs for the first time with H-1 HR-MAS NMR spectroscopy, we show that these cells behave distinctly and that they have different metabolic patterns in function of their stage of maturity. Moreover, their response to FGF-2 and anosmin-1 differs in relation to their developmental stage and in function of the species. Our data reveal that the behaviour of adult human and mouse OPCs differs in a very dynamic way that should be considered when testing drugs and for the proper design of effective pharmacological and/or cell therapies for MS.